Project Grant P20AP00140

This Project Grant award of $320,000.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program, supports research to understand the mechanisms behind radiotherapy resistance in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). The award recipient, Baylor College of Medicine, is utilizing a novel genetically engineered mouse model to study how alterations in the...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $728,577 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The research aims to investigate the mechanisms by which the ATP receptor P2RX4 influences profibrotic pathways in fibroblasts, a key driver of idiopathic pulmonary fibrosis (IPF)...

This $719,882 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate lung-specific immune pathways driving post-hematopoietic cell transplant (HCT) lung injury in pediatric patients. The goal is to identify cellular and molecular targets for precision diagnostics and therapeutics. Key objectives include: Elucidating peripheral blood correlates of post-HCT lung injury by contrasting...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $573,416 project grant to The Geneva Foundation to conduct a study titled "PRE-DIAGNOSTIC SERUM CONCENTRATIONS OF PER- AND POLYFLUOROALKYL SUBSTANCES AND RISK OF TESTICULAR GERM CELL TUMORS AMONG ACTIVE-DUTY SERVICEMEN." The 3-year grant, which began on Sep 30, 2023, will support research investigating the relationship between exposure to per- and polyfluoroalkyl substances...

The National Heart Lung and Blood Institute (NHLBI) awarded a $709,902 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Sex, HIV, and Air Pollution Effects on Post-TB Lung Disease (SHAPE PTLD)," aims to establish a well-characterized cohort of post-tuberculosis (TB) individuals in Uganda and investigate the impact of sex, HIV serostatus, and air pollution exposure on...

The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...

This Project Grant award of $186,896 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to evaluate the impact of adverse childhood experiences (ACEs) screening and behavioral-social support on health outcomes for obstructive lung diseases such as asthma and COPD. The award recipient, the Regents of the University of California, San Francisco (UCSF), will leverage data from a large-scale ACES screening program implemented by...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $684,814 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the suppression of alveolar stem cells by tissue-resident lymphocytes in emphysema. The research aims to investigate how tissue factors in the lung alter the inflammatory response to viral infections, leading to the loss of alveolar type 2...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) provides $515,812 to The Johns Hopkins University to study the progression of HPV-related oropharynx cancer (HPV-OPC) and how it differs between individuals with and without HIV. The study aims to: 1) characterize the impact of HIV on oral HPV16 persistence, 2) evaluate the performance of oral and blood biomarkers for...

The National Heart, Lung, and Blood Institute awarded a $712,268 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct the "Uganda Lung Health Study". This 5-year longitudinal cohort study will follow 800 adolescents and adults, evenly balanced by sex and HIV status, to investigate the intersection of HIV, sex, and chronic obstructive pulmonary disease (COPD)...